Open Label Trial of GLYX-13 in Individuals With Obsessive-Compulsive Disorder
| Status: | Completed |
|---|---|
| Conditions: | Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 55 |
| Updated: | 4/21/2016 |
| Start Date: | October 2014 |
| End Date: | February 2016 |
This research study tests whether GLYX-13 - an experimental drug that acts on a brain
receptor called NMDA - can decrease symptoms of OCD within hours. This is not a treatment
study. Results from this study will allow doctors and researchers to better understand if
you and others with OCD may respond to a class of medications that target the NMDA brain
receptor.
receptor called NMDA - can decrease symptoms of OCD within hours. This is not a treatment
study. Results from this study will allow doctors and researchers to better understand if
you and others with OCD may respond to a class of medications that target the NMDA brain
receptor.
Inclusion Criteria for Patients with No medication Washout:
- Age 18-55
- Physically healthy and not currently pregnant
- Primary Diagnosis of OCD
- currently off all psychotropic medications and other drugs
- Able to provide informed consent
Exclusion Criteria for Patients with No Medication Washout:
- Psychiatric conditions that make participation unsafe (schizophrenia [either self or
first degree relative e.g. siblings, parents], history of violence, severe
depression, eating disorder, substance abuse in prior year[including nicotine],
lifetime substance dependence disorder [except nicotine])
- Female patients who are either pregnant or nursing
- Enrolled in or planning to enroll in Cognitive Behavioral Therapy.
- Medical conditions that make participation unsafe (e.g., high blood pressure, head
injury)
- Currently on medications that make participation unsafe
- History of allergy, sensitivity, or intolerance to N-methyl-D-aspartate receptor
(NMDAR) ligands including ketamine, dextromethorphan, memantine, methadone,
destropropoxyphene, or ketobemidone.
Inclusion Criteria for Patients with Medication Washout:
- Age 18-55
- Physically healthy and not currently pregnant
- Primary Diagnosis of OCD
- Currently on adequate dose of medication for treatment of OCD, but have not achieved
at least partial remission and able to handle a medication washout.
- Able to provide informed consent
Exclusion Criteria for Patients with Medication Washout:
- Psychiatric conditions that make participation unsafe (schizophrenia [either self or
first degree relative e.g. siblings, parents], history of violence, severe
depression, eating disorder, substance abuse in prior year[including nicotine],
lifetime substance dependence disorder [except nicotine])
- Female patients who are either pregnant or nursing
- Enrolled in or planning to enroll in Cognitive-Behavioral Therapy.
- Patient judged unlikely to be able to tolerated a medication washout.
- Medical conditions that make participation unsafe (e.g., high blood pressure, head
injury)
- Currently on medications that make participation unsafe
- History of allergy, sensitivity, or intolerance to N-methyl-D-aspartate receptor
(NMDAR) ligands including ketamine, dextromethorphan, memantine, methadone,
destropropoxyphene, or ketobemidone.
We found this trial at
1
site
Click here to add this to my saved trials
